USPTO serial 79111670
EXONHIT
Reviewed by CopyMark Law Group
Reg. 4281253Status 404
- Filing date
- Status date
- Registration date
- Jan 29, 2013
- Examiner
- HOFFMAN, DAVID AARON
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with EXONHIT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical products and compositions, namely, nucleic acids attached to a solid medium for industrial and scientific use; fissile chemical elements intended for scientific research or laboratory research, namely, reagents, consumables, chemical entities and compounds; chemical preparations for nucleic acids attached to a solid medium for scientific purposes, chemical preparations for scientific analyses other than for medical or veterinary purposes; biological preparations other than for medical or veterinary purposes, namely, blood for the quantification of nucleic acid content; chemical preparations for scientific purposes other than for medical or veterinary use; chemical reagents or products for laboratory analyses, namely, nucleic acids for monitoring and analyzing the expression of genes, for identifying diagnostic targets and therapeutic products, and for conducting research on pharmacogenetics and genotoxicity in connection with pharmacology, food, chemistry, cosmetology, plant health and veterinary sciences; chemical preparations intended for scientific purposes, namely, libraries of nucleic acids for monitoring and analyzing the expression of genes, for identifying diagnostic targets and therapeutic products, and for leading research on pharmacogenetics and genotoxicity in connection with pharmacology, food, chemistry, cosmetology, plant health and veterinary sciences; chemical preparations intended for scientific purposes, namely, DNA fragments for decoding genes affected by diseases or for revealing the transcriptomic signature of patients affected by diseases, and DNA fragments for revealing and analyzing the expression of genes in connection with human medicine, pharmacological medicine and veterinary science | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical products for the treatment of diseases, namely, Alzheimer disease and other neurodegenerative diseases and cancer; reagents and consumables for diagnostic purposes and diagnostic media intended for medical purposes, namely, reagents, consumables and media intended for tests, namely, tests based on blood biomarkers for identifying patients affected by diseases or those at risk of developing a disease and for identifying patients responding to specific personalized treatments; biological acidic products and preparations for pharmaceutical purposes, namely, pharmaceutical preparations for diagnosing diseases, namely, Alzheimer disease and other neurodegenerative diseases and cancer; capsules sold empty for medicines and diagnostic tests; chemico-pharmaceutical preparations for diagnosing, preventing and treating diseases, namely, Alzheimer disease and other neurodegenerative diseases and, cancer; biopharmaceutical products, namely, reagents, consumables, chemical entities and compounds for diagnosing, preventing and treating diseases, namely, Alzheimer disease and other neurodegenerative diseases and cancer ; chemical preparations for medical, pharmaceutical or veterinary purposes, namely, chemicals for diagnosing Alzheimer disease and other neurodegenerative diseases and cancer, especially chemical preparations for diagnosing diseases in the nature of neurodegenerative diseases and cancers; medical diagnostic products and clinical diagnostic products, namely, probes and kits for medical and clinical diagnosis comprised of nucleic acid libraries and nucleic acids on DNA chips; DNA libraries and RNA libraries for medical diagnostic purposes; nucleic acid sequences intended for use in chips for medical purposes and medical diagnostic purposes, namely, for decoding genes affected by diseases or revealing the transcriptomic signature of patients affected by diseases; enzymes or enzyme preparations for medical or veterinary purposes, namely, enzyme stabilizers and enzymatic substrates for use as ingredients in medicines for the treatment of diseases; reagents contained in diagnostic test kits for medical use for taking blood samples required for the preservation of the biological material under analysis in order to carry out the test under the appropriate conditions | SECTION 71 - CANCELLED | — |
| 010 | Surgical, medical, dental and veterinary apparatus and instruments, particularly for identifying, assessing the seriousness of, assessing prognoses of, and measuring the progression of diseases, namely, Alzheimer disease and other neurodegenerative diseases, and cancer; medical devices using DNA chips for analyzing blood; apparatus for analyzing blood; apparatus intended for medical diagnosis, namely, materials for taking blood contained in kits for taking blood samples and comprised of medical instruments for taking blood; medical instruments for taking blood, collecting of DNA for diagnosing diseases, and materials required for the preservation of the biological material under analysis in order to carry out the test under the appropriate conditions, namely, tubes, syringes and storage containers; spoons for administering medicine; specially adapted containers for the application of medicines, namely, small bags and pouches for use in administering medicines; probes for medical purposes; syringes for medical purposes | SECTION 71 - CANCELLED | — |
| 042 | Research and development for others of pharmaceutical molecules or biological markers for diagnostic purposes and medicines for treating diseases; chemical analyses; chemical research; chemical services, namely, analysis of RNA genes, tissues and blood samples; biotechnological scientific project studies for identifying people suffering from diseases and to measure the seriousness, prognoses, progression and conversion of the disease and to determine how patients respond to treatments, especially personalized treatments; research and development of new products for others; biological research; biotechnological research; technical research in the field of biotechnology; biotechnological analysis services; laboratory analyses, namely, quantification of nucleic acid content intended for medical and scientific research; consultancy in the field of biotechnology | SECTION 71 - CANCELLED | — |
| 044 | Medical services; veterinary services; medical assistance services; consultancy in the field of pharmacy, namely, to assist in the selection of individuals affected by diseases for the purpose of clinical trials and to offer targeted care solutions and personalized treatments; hospitals; pharmaceutical industry services, namely, to provide advice in the fields of biotechnology and pharmacy; and pharmacist's services to make up prescriptions, namely, geriatric and/or neurological services, in order to facilitate diagnoses and treatment; health care; telemedicine services | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by DIAXONHIT
- Other trademarks owned by EXONHIT S.A.
- Other trademarks owned by EXONHIT S.A.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named EXONHIT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 26, 2022 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Jun 26, 2022 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Jul 17, 2020 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Jun 15, 2020 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Jun 15, 2020 | INPC | INVALIDATION PROCESSED | — |
| Apr 30, 2020 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Aug 30, 2019 | C71T | CANCELLED SECTION 71 | — |
| Jan 29, 2018 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Nov 20, 2014 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| May 25, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 29, 2013 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 29, 2013 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 29, 2013 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 29, 2013 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 18, 2012 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Nov 13, 2012 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 13, 2012 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 24, 2012 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 24, 2012 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 24, 2012 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 9, 2012 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 5, 2012 | ALIE | ASSIGNED TO LIE | — |
| Sep 22, 2012 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 21, 2012 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 21, 2012 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 21, 2012 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Aug 27, 2012 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Aug 27, 2012 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 27, 2012 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 23, 2012 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 23, 2012 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 23, 2012 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 23, 2012 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 11, 2012 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 18, 2012 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 18, 2012 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 17, 2012 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 16, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 14, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| May 8, 2012 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 4, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| May 4, 2012 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 3, 2012 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |